Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Receivables - Accured (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Receivables - Accured for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables - Accured fell 14.13% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 14.13% decrease, with the full-year FY2025 number at $1.1 million, down 14.13% from a year prior.
  • Receivables - Accured was $1.1 million for Q4 2025 at Fulcrum Therapeutics, up from $934000.0 in the prior quarter.
  • In the past five years, Receivables - Accured ranged from a high of $1.7 million in Q4 2023 to a low of $102000.0 in Q1 2021.
  • A 5-year average of $927050.0 and a median of $1.1 million in 2024 define the central range for Receivables - Accured.
  • Biggest YoY gain for Receivables - Accured was 449.3% in 2021; the steepest drop was 42.37% in 2021.
  • Fulcrum Therapeutics' Receivables - Accured stood at $473000.0 in 2021, then soared by 80.13% to $852000.0 in 2022, then surged by 100.94% to $1.7 million in 2023, then fell by 27.22% to $1.2 million in 2024, then fell by 14.13% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Receivables - Accured are $1.1 million (Q4 2025), $934000.0 (Q3 2025), and $1.3 million (Q2 2025).